Connor, Clark & Lunn Investment Management (CC&L)
SCLN

Connor, Clark & Lunn Investment Management (CC&L)’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-202,525
Closed -$2.23M – 975
2016
Q1 		$2.23M Sell
202,525
-30,375
-13% -$270K 0.02% 322
2015
Q4 		$2.14M Buy
232,900
+25,225
+12% +$211K 0.02% 328
2015
Q3 		$1.44M Sell
207,675
-38,725
-16% -$332K 0.01% 344
2015
Q2 		$2.42M Buy
246,400
+3,300
+1% +$30.1K 0.02% 215
2015
Q1 		$2.15M Sell
243,100
-23,300
-9% -$186K 0.02% 222
2014
Q4 		$2.33M Buy
266,400
+18,700
+8% +$151K 0.02% 211
2014
Q3 		$1.71M Buy
247,700
+63,600
+35% +$381K 0.01% 230
2014
Q2 		$1.03M Buy
184,100
+9,700
+6% +$47.2K 0.01% 319
2014
Q1 		$876K Buy
174,400
+22,700
+15% +$110K 0.01% 400
2013
Q4 		$812K Sell
151,700
-27,200
-15% -$131K 0.01% 413
2013
Q3 		$932K Buy
178,900
+5,700
+3% +$31.7K 0.01% 275
2013
Q2 		$906K Buy
+173,200
New +$824K 0.01% 274

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s SCLN Position: Q2 2016 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q2 2016, closing a stake of 202,525 shares — an estimated $2.23M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in SCLN in Q2 2013 and held it in 12 quarters. The position peaked at $2.42M in Q2 2015. 151 funds tracked by Wall St. Rank hold SCLN as of Q2 2016.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Sciclone Pharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 202,525 Sciclone Pharmaceuticals Inc shares in Q2 2016, an estimated $2.23M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 12 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Sciclone Pharmaceuticals Inc position peaked at $2.42M in Q2 2015.
  • 151 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q2 2016.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2016, filed 15 Aug 2016.